A. Ciarlo

694 total citations
16 papers, 372 citations indexed

About

A. Ciarlo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, A. Ciarlo has authored 16 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Hepatology. Recurrent topics in A. Ciarlo's work include Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (10 papers) and Gastric Cancer Management and Outcomes (9 papers). A. Ciarlo is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (10 papers) and Gastric Cancer Management and Outcomes (9 papers). A. Ciarlo collaborates with scholars based in Italy and Canada. A. Ciarlo's co-authors include Alfredo Falcone, Fotios Loupakis, Gianluca Masi, D. Amoroso, Lisa Salvatore, Elisa Sensi, Samanta Cupini, Lorenzo Fornaro, Cristina Granetto and Chiara Cremolini and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

A. Ciarlo

16 papers receiving 365 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Ciarlo Italy	7	301	144	119	95	64	16	372
Quanren Wang China	1	245 0.8×	131 0.9×	148 1.2×	61 0.6×	49 0.8×	2	368
See‐Chun Phan United States	11	303 1.0×	69 0.5×	249 2.1×	66 0.7×	89 1.4×	17	435
Xavier Chopin‐Laly France	10	347 1.2×	87 0.6×	148 1.2×	216 2.3×	66 1.0×	13	498
Wanda Honeycutt United States	9	270 0.9×	54 0.4×	115 1.0×	73 0.8×	106 1.7×	20	363
Jean-Claude Vedovato France	9	296 1.0×	66 0.5×	137 1.2×	54 0.6×	74 1.2×	13	340
S. Tsousis Greece	6	316 1.0×	134 0.9×	134 1.1×	65 0.7×	32 0.5×	8	390
B. Killing Germany	7	288 1.0×	48 0.3×	141 1.2×	57 0.6×	40 0.6×	9	329
Silvija Kraljevic United States	8	178 0.6×	157 1.1×	142 1.2×	24 0.3×	67 1.0×	15	327
Yoriko Takezako Japan	7	293 1.0×	74 0.5×	188 1.6×	182 1.9×	47 0.7×	13	408
N. E. Kemeny United States	10	406 1.3×	116 0.8×	131 1.1×	221 2.3×	83 1.3×	24	521

Countries citing papers authored by A. Ciarlo

Since Specialization

Citations

This map shows the geographic impact of A. Ciarlo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Ciarlo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Ciarlo more than expected).

Fields of papers citing papers by A. Ciarlo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Ciarlo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Ciarlo. The network helps show where A. Ciarlo may publish in the future.

Co-authorship network of co-authors of A. Ciarlo

This figure shows the co-authorship network connecting the top 25 collaborators of A. Ciarlo. A scholar is included among the top collaborators of A. Ciarlo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Ciarlo. A. Ciarlo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

1.

Rosati, Gerardo, Chiara Alessandra Cella, Luigi Cavanna, et al.. (2022). A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial. Gastric Cancer. 25(4). 783–793. 4 indexed citations

2.

Bartolomeo, Maria Di, A. Ciarlo, Alessandro Bertolini, et al.. (2015). Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. European Journal of Cancer. 51(4). 473–481. 15 indexed citations

3.

Buzzoni, Roberto, Sara Pusceddu, Emilio Bajetta, et al.. (2014). Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Annals of Oncology. 25(8). 1597–1603. 60 indexed citations

4.

Salvatore, Lisa, Fotios Loupakis, Chiara Cremolini, et al.. (2014). Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.. Journal of Clinical Oncology. 32(15_suppl). TPS3664–TPS3664. 1 indexed citations

5.

Allegrini, Giacomo, Teresa Di Desidero, Anna Fioravanti, et al.. (2012). Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis. 15(2). 275–286. 50 indexed citations

6.

Bajetta, Emilio, Irene Floriani, Maria Di Bartolomeo, et al.. (2012). Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer.. Journal of Clinical Oncology. 30(18_suppl). LBA4001–LBA4001. 5 indexed citations

7.

Bajetta, Emilio, Irene Floriani, Maria Di Bartolomeo, et al.. (2012). Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer.. Journal of Clinical Oncology. 30(15_suppl). LBA4001–LBA4001. 10 indexed citations

8.

Masi, Gianluca, Fotios Loupakis, Lisa Salvatore, et al.. (2010). Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. The Lancet Oncology. 11(9). 845–852. 190 indexed citations

9.

Bajetta, Emilio, Irene Floriani, Maria Di Bartolomeo, et al.. (2010). ITACA-S (Intergroup trial of adjuvant chemotherapy in adenocarcinoma of the stomach) trial: comparison of a sequential treatment versus a 5-FU/LV regimen for radically resecate gastric cancer. Tolerability and feasibility of a randomized study. CINECA IRIS Institutial research information system (University of Pisa). 10. 1 indexed citations

10.

Masi, Gianluca, Enrico Vasile, Fotios Loupakis, et al.. (2009). Bevacizumab (BV) in combination with folfoxiri (Irinotecan, Oxaliplatin and Infusional 5FU/LV) as first-line treatment of metastatic colorectal cancer (mCRC): a phase II trial by the GONO GROUP. CINECA IRIS Institutial research information system (University of Pisa). 20. 2 indexed citations

11.

Salvatore, Lisa, Fotios Loupakis, Gabriella Fontanini, et al.. (2009). 6060 KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts). European Journal of Cancer Supplements. 7(2). 339–339. 3 indexed citations

12.

Masi, Gianluca, Lisa Salvatore, Lorenzo Fornaro, et al.. (2009). 6081 Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updated results of a phase II G.O.N.O. trial. European Journal of Cancer Supplements. 7(2). 346–346. 2 indexed citations

13.

Masi, Gianluca, Fotios Loupakis, Giacomo Giulio Baldi, et al.. (2008). First-line treatment of metastatic colorectal cancer (MCRC) with folfoxiri (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the G.O.N.O. Group. CINECA IRIS Institutial research information system (University of Pisa). 2 indexed citations

14.

Falcone, Alfredo, Gianluca Masi, Fotios Loupakis, et al.. (2008). FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group. Journal of Clinical Oncology. 26(15_suppl). 4031–4031. 17 indexed citations

15.

Masi, Gianluca, Fotios Loupakis, Enrico Vasile, et al.. (2008). Phase II study of first-line treatment in metastatic colorectal cancer (MCRC) with GONO-FOLFOXIRI (Irinotecan, Oxaliplatin and Infusional 5FU/LV) plus Bevacizumab. CINECA IRIS Institutial research information system (University of Pisa). 3 indexed citations

16.

Leo, Angelo Di, A. Ciarlo, Massimiliano Panella, et al.. (2004). Controversies in the adjuvant treatment of breast cancer: the role of taxanes. Annals of Oncology. 15. iv17–iv21. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact